An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Epizyme To Participate in H.C. Wainwright Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Epizyme (NASDAQ: EPZM) announced that CEO Grant Bogle and Senior Medical Advisor Shefali Agarwal will present at the H.C. Wainwright Global Investment Conference.
A pre-recorded fireside chat will be available at 7:00 AM EST on May 24, 2022, accessible via the investor section of www.epizyme.com and archived for 60 days.
Epizyme is dedicated to developing transformative therapies for cancer patients through innovative epigenetic approaches.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference.
A pre-recorded fireside chat will be available to play on demand stating at 7:00am EST on Tuesday, May 24, 2022. It can be found in the investor section of the Company’s website at www.epizyme.com and will be archived after 60 days following the presentation.
About Epizyme, Inc. Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit www.epizyme.com.
